Adoptive T Cell Therapy for Solid Tumors: Pathway to Personalized Standard of Care

Area of Science:

• Immunology and Cancer Therapy
• Cellular Therapy
• Oncology

Background:

• Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TILs) is a personalized medicine approach for solid tumors.
• TIL-ACT leverages the patient's immune system to target cancer but faces challenges with non-response.
• Tumor heterogeneity presents a significant hurdle for developing universal cancer treatments.

Purpose of the Study:

• To review the evolution of TIL-based ACT.
• To identify key resistance mechanisms limiting TIL-ACT efficacy.
• To explore novel strategies for overcoming resistance and enhancing therapeutic outcomes.

Main Methods:

• Literature review of advancements in TIL isolation and ex vivo expansion.
• Analysis of documented resistance pathways in TIL therapy.
• Synthesis of emerging strategies to improve TIL-ACT effectiveness.

Main Results:

• TIL-ACT can induce durable tumor regression in some patients.
• Patient response to TIL-ACT is variable, with significant non-response rates.
• Various intrinsic and extrinsic factors contribute to TIL-therapy resistance.

Conclusions:

• Refining TIL protocols (isolation, expansion, infusion) is crucial for improving efficacy.
• Understanding and overcoming resistance mechanisms are key to unlocking TIL-ACT's full potential.
• Future research should focus on novel strategies to enhance TIL-ACT in diverse patient populations.